Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pneumococcal Pneumonia
Conditions
Pneumococcal Pneumonia, Influenza
Trial Timeline
Nov 1, 2015 → Aug 1, 2016
NCT ID
NCT02592486About Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®
Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe® is a approved stage product being developed by Merck for Pneumococcal Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT02592486. Target conditions include Pneumococcal Pneumonia, Influenza.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02592486 | Approved | Completed |
Competing Products
20 competing products in Pneumococcal Pneumonia